Abbisko Therapeutics

Focus: Abbisko Therapeutics is a Shanghai-based biotech company focused on immunomodulators for cancer, operating a diversified pipeline across oncology and immunology indications.

Oncology Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Abbisko Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Abbisko Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Interventions

Achondroplasia

N/A

No Interventions

Achondroplasia

N/A

Clinical Trials (1)

Help build intelligence for Abbisko Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a Phase 3 program (pimicotinib for tenosynovial giant cell tumor) with 13 active trials, offering visibility into regulatory milestones and potential commercialization
Multi-indication oncology pipeline with 13 programs across phases 1-3, providing diverse project exposure and learning across cancer modalities
Shanghai headquarters positions you at the center of Asian biotech innovation with access to Chinese clinical trial infrastructure and emerging markets

Watch Out For

Only 4 active job openings signal minimal hiring velocity and limited career advancement or role mobility within the organization
No public funding, revenue, or financial data available suggests limited transparency; pre-revenue status implies burn rate concerns and potential financing risk

Generated by Claude from Abbisko Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT07301463A Study in Children With Achondroplasia

N/A

ABSK121-NX

Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT05627063A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Phase 1

ABSK091

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT05533788ABSK091 Food Effect Study in Healthy Subjects

Phase 1

ABSK112

Non-Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT06225804A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Phase 1

Part A ABSK201 and Itraconazole

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT06089733A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Phase 1

ABSK021

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT06322706A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Phase 1

ABSK021 with fed state

Neoplasms

Phase 1

Clinical Trials (1)

NCT05280483ABSK021 Food Effect Study in Healthy Subjects

Phase 1

ABSK021

Neoplasms

Phase 1

Clinical Trials (1)

NCT04192344A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Phase 1

[14C]ABSK011

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT06896760A Mass Balance Study of [14C]ABSK011

Phase 1

[14C]ABSK011

Healthy Subjects

Phase 1

ABSK131

Advanced/Metastatic Solid Tumors

Phase 1

Clinical Trials (1)

NCT07288957A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

Phase 1

X4P-001

Triple Negative Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT05103917A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Phase 1/2

ABSK141

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT07417189A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Phase 1/2

ABSK061

Achondroplasia

Phase 1/2

ABSK-011

Hepatocellular Carcinoma

Phase 2

Clinical Trials (4)

NCT07327034ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Phase 2

NCT05441475A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Phase 2

NCT06306872A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

Phase 1

+1 more

ABSK061

Achondroplasia

Phase 2

Clinical Trials (3)

NCT07297875A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Phase 1/2

NCT05244551A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Phase 1

NCT07007546A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

Phase 1

ABSK043

Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (4)

NCT07164170A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Phase 2

NCT06668103A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Phase 2

NCT06632262A Phase 2 Clinical Study of ABSK061 and ABSK043

Phase 2

+1 more

irpagratinib

Hepatocellular Carcinoma

Phase 2

Clinical Trials (1)

NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Phase 2

AZD4547

Urothelial Carcinoma

Phase 2

Clinical Trials (2)

NCT05775874A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Phase 2

NCT05086666A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Phase 1/2

pimicotinib

Tenosynovial Giant Cell Tumor

Phase 3

Clinical Trials (5)

NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Phase 3

NCT06111274A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Phase 2

NCT06186804A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Phase 2

+2 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 36 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

20 pipeline

Marketed

Pipeline